Objetivo
Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org 2010).
Even modest therapeutic advances that delay disease onset and progression could significantly reduce the global burden of the disease and the level of care required by patients. While there are symptomatic-based drug therapies available for AD, these medications do not prevent the disease process itself. There is therefore an imperative to develop new treatments for AD that have disease modifying effects.
This double-blind placebo controlled study will test the efficacy and safety of nilvadipine in 500 subjects with mild to moderate AD over a treatment period of 18 months. There is a strong scientific rationale for this study: Nilvadipine, a licensed calcium channel enhances Aß clearance from brain and restores cortical perfusion in mouse models of AD. Nilvadipine is safe and well tolerated in AD patients and clinical studies with this medication have shown stabilization of cognitive decline and reduced incidence of AD, pointing to both symptomatic and disease modifying benefits. Male and female patients with mild to moderate AD aged between 50 and 90 with a range of medical morbidities and frailty will be included in the study. If this trial is successful, nilvadipine would represent an advance in the treatment of AD patients and would have a major impact on the health and social care costs incurred in Europe by this neurodegenerative disorder. Furthermore, the creation of the NILVAD network will support future clinical trials and research innovation in AD across Europe.
Ámbito científico
Convocatoria de propuestas
FP7-HEALTH-2011-two-stage
Consulte otros proyectos de esta convocatoria
Régimen de financiación
CP-FP - Small or medium-scale focused research projectCoordinador
D02 CX56 DUBLIN 2
Irlanda
Ver en el mapa
Participantes (16)
2 Dublin
Ver en el mapa
1736 SENNINGERBERG
Ver en el mapa
34243 SARASOTA
Ver en el mapa
CORK
Ver en el mapa
4 Dublin
Ver en el mapa
La participación finalizó
80333 Muenchen
Ver en el mapa
WC2R 2LS London
Ver en el mapa
20156 Milano
Ver en el mapa
59037 Lille
Ver en el mapa
89081 Ulm
Ver en el mapa
6720 Szeged
Ver en el mapa
405 30 Goeteborg
Ver en el mapa
T12 YN60 Cork
Ver en el mapa
546 36 THESSALONIKI
Ver en el mapa
6525 XZ Nijmegen
Ver en el mapa
8 DUBLIN
Ver en el mapa